Hims & Hers Health, Inc.

https://www.hims.com/

Hims & Hers Health, Inc. is a multi-specialty telehealth platform established in 2017, connecting consumers with licensed healthcare professionals for personalized health and wellness solutions. The company's mission is "to help the world feel great through the power of better health," aiming to make healthcare accessible and convenient. Its headquarters are located in San Francisco, California, United States.

The platform offers a range of prescription and non-prescription products and services across various health categories, including sexual health, hair care, mental health, skincare, dermatology, hormone health, and weight loss. This encompasses medical consultations, post-consultation support, and laboratory testing services. Hims & Hers operates on a direct-to-consumer model, primarily targeting digitally native individuals aged 18-45 who value convenience, discretion, and personalized online healthcare. While initially focused on men's health, the "Hers" brand has significantly expanded, with women comprising a growing portion of its subscriber base.

Led by co-founder and CEO Andrew Dudum, Hims & Hers has positioned itself as a virtual front door to the healthcare system. Recent strategic developments include expanding into high-demand treatment categories such as weight loss, notably with GLP-1 therapies, and exploring partnerships with pharmaceutical companies like Novo Nordisk and Eli Lilly to enhance access to these medications. The company continues to invest in AI and personalized care to improve service delivery and maintain its market position, serving a subscriber base that reached 2.4 million by mid-2025.

Latest updates

Hims & Hers Adds Marketing Vet to Board Amid Growth Push

Event summary

  • Hims & Hers has nominated Kofi Amoo-Gottfried to its board of directors, to be voted on at the June 2026 shareholder meeting.
  • Amoo-Gottfried previously served as CMO at DoorDash and held leadership roles at Meta, with experience at major marketing agencies.
  • The board will decrease in size to 9 members following the election, with Christiane Pendarvis and Dr. Pat Carroll not seeking re-election.
  • Dr. Pat Carroll will continue in his role as Global Chief Medical Officer.
  • Several returning board members are also nominated: Andrew Dudum, Deb Autor, Dr. Toby Cosgrove, Anja Manuel, Christopher Payne, Andrea Perez, Käre Schultz, and David Wells.

The big picture

The addition of Kofi Amoo-Gottfried to the Hims & Hers board reflects a strategic move to bolster the company’s marketing capabilities as it seeks to solidify its position as a leading digital health and wellness platform. His experience with high-growth consumer brands like DoorDash and Meta suggests a desire to accelerate user acquisition and brand awareness. This also comes as the telehealth market becomes increasingly crowded, requiring stronger brand differentiation to maintain market share.

What we're watching

Marketing Focus
Amoo-Gottfried’s appointment signals a heightened emphasis on brand building and consumer perception, which will be critical for Hims & Hers as it navigates increasing competition in the telehealth space.
Governance Shift
The reduction in board size and departure of Pendarvis and Carroll suggest a potential shift in strategic priorities, and whether the remaining directors can maintain the company’s policy and medical expertise.
Execution Risk
The success of Amoo-Gottfried’s marketing guidance will depend on Hims & Hers’ ability to translate those strategies into tangible user acquisition and retention, especially given the company’s current valuation.

Hims & Hers Broadens GLP-1 Access via Novo Nordisk Partnership

Event summary

  • Hims & Hers is now offering a range of Novo Nordisk’s FDA-approved GLP-1 medications, including Wegovy, to eligible customers.
  • The collaboration aims to provide more affordable access to GLP-1 medications with various dosages and delivery methods.
  • Hims & Hers is introducing a new weight loss membership program starting at $39/month (plus medication costs).
  • Prices for GLP-1 medications begin at $149 per month, requiring a Hims & Hers membership.

The big picture

This partnership represents a significant expansion for Hims & Hers, positioning them as a dominant player in the rapidly growing digital therapeutics and weight management market. Novo Nordisk’s willingness to partner with a direct-to-consumer platform signals a shift in pharmaceutical distribution strategies, potentially bypassing traditional pharmacy channels. The move also underscores the increasing consumer demand for accessible and affordable weight loss solutions, driven by the efficacy of GLP-1 medications.

What we're watching

Pricing Pressure
The $149/month starting price point, while seemingly affordable, will be under scrutiny as Hims & Hers scales and competition intensifies; margin compression is a risk if they need to lower prices to maintain volume.
Clinical Oversight
The reliance on provider clinical judgment for GLP-1 access creates a potential bottleneck and exposes Hims & Hers to liability if prescribing practices are deemed inappropriate or medically questionable.
Compounding Risk
The plan to offer compounded GLP-1s for a limited set of customers introduces regulatory and quality control risks that could damage Hims & Hers’ reputation and expose them to legal challenges.

Hims & Hers Taps Eli Lilly Vet to Bolster Communications Amid Growth Push

Event summary

  • Kathryn Beiser has been appointed Chief Communications Officer (CCO) at Hims & Hers.
  • Beiser will report directly to CEO Andrew Dudum and oversee both external and internal communications.
  • She previously held senior communications roles at Discover, Kaiser Permanente, Eli Lilly, and Edelman.
  • Hims & Hers cites Beiser's experience in navigating transformative growth phases and regulated industries as key factors in the appointment.

The big picture

The appointment of a seasoned communications executive like Beiser signals Hims & Hers' intent to proactively manage its narrative as it expands internationally and navigates a complex regulatory landscape. Her experience at Eli Lilly, a company facing significant scrutiny regarding drug pricing and marketing, suggests a focus on transparency and stakeholder engagement. This move comes as telehealth and direct-to-consumer healthcare models face increasing pressure to demonstrate value and address concerns around patient safety and data privacy.

What we're watching

Brand Perception
Beiser's track record suggests a focus on reputation management; investors should monitor how her strategies impact Hims & Hers' brand sentiment and customer trust, particularly given the company's reliance on direct-to-consumer marketing.
Regulatory Scrutiny
With Beiser's experience in regulated industries, the company will likely face increased scrutiny regarding its marketing and data privacy practices, potentially impacting expansion plans and profitability.
Growth Execution
The success of Hims & Hers' international growth ambitions hinges on effective communication; the pace at which Beiser can translate the company's vision into a compelling narrative will be a key indicator of its ability to penetrate new markets.

Hims & Hers Bundles Wellness Services in Subscriber Loyalty Push

Event summary

  • Hims & Hers launched 'Hims & Hers Benefits,' a program offering discounts to active subscribers.
  • Subscribers receive a $400 discount on Prenuvo whole-body MRI scans and up to $350 off Eight Sleep’s Pod 5 series.
  • Hims & Hers states it will not profit from these benefits, passing all savings directly to subscribers.
  • The program aims to expand the value proposition of a Hims & Hers subscription, integrating broader health and wellness services.
  • The initiative began March 10, 2026, and is positioned as the first phase of a larger benefits program.

The big picture

Hims & Hers is attempting to deepen subscriber engagement and differentiate itself in a crowded telehealth market by bundling premium wellness services. This strategy reflects a broader trend among subscription-based businesses to offer more holistic value propositions beyond core services. The move also signals a shift towards preventative and proactive healthcare, capitalizing on growing consumer interest in personalized wellness solutions, but introduces new operational and financial complexities.

What we're watching

Customer Retention
The success of Hims & Hers Benefits hinges on whether the added value meaningfully reduces churn and attracts new subscribers, justifying the cost of the partnerships.
Partner Dependency
Hims & Hers' reliance on Prenuvo and Eight Sleep creates potential vulnerabilities if those partnerships dissolve or the discount structures become unsustainable.
Margin Pressure
While Hims & Hers claims to not profit from the benefits, the program's long-term impact on overall margins warrants close monitoring, particularly if subscriber acquisition costs remain high.

Hims & Hers Shifts US Weight Loss Strategy, Partners with Novo Nordisk

Event summary

  • Hims & Hers is collaborating with Novo Nordisk to align its US weight loss strategy with its global model.
  • The company will now prioritize FDA-approved GLP-1 medications and offer compounded semaglutide on a limited basis.
  • Hims & Hers will add Ozempic® and Wegovy® to its platform later this month, including various dosages and formulations.
  • The agreement resolves a pending lawsuit between Hims & Hers and Novo Nordisk without prejudice.

The big picture

Hims & Hers' strategic pivot reflects the rapid evolution of the GLP-1 weight loss market, where branded medications have become increasingly accessible and affordable. This shift represents a move away from the company’s earlier reliance on compounded drugs and towards a more mainstream, FDA-approved model. The partnership with Novo Nordisk signals a consolidation of power within the weight loss space, potentially reshaping the competitive landscape and impacting smaller telehealth platforms.

What we're watching

Customer Transition
The success of Hims & Hers' strategy hinges on the ability to seamlessly transition existing compounded semaglutide users to branded FDA-approved medications, which could impact customer retention and platform engagement.
Regulatory Scrutiny
Increased reliance on branded GLP-1s may draw greater regulatory scrutiny towards Hims & Hers' platform and its role in facilitating access to these medications, potentially impacting operational costs and compliance requirements.
Novo Nordisk Dependence
Hims & Hers' future success is now heavily reliant on the ongoing partnership with Novo Nordisk, making it vulnerable to changes in Novo Nordisk's pricing, product availability, or strategic priorities.

Hims & Hers Acquires Eucalyptus for $1.15 Billion to Expand International Telehealth Footprint

Event summary

  • Hims & Hers has agreed to acquire Eucalyptus, an Australian digital health provider, for up to $1.15 billion.
  • The acquisition will be financed primarily with existing cash and future operating cash flows, with $240 million payable in cash at closing.
  • Tim Doyle, current CEO of Eucalyptus, will become SVP of International at Hims & Hers.
  • Eucalyptus has an annual revenue run-rate exceeding $450 million USD and has served over 775,000 customers.
  • The deal is expected to close in mid-2026 and is subject to customary closing conditions, including regulatory approvals.

The big picture

This acquisition signals Hims & Hers’ aggressive push to become a global consumer health platform, moving beyond its US dominance. The $1.15 billion price tag reflects the growing investor interest in digital health solutions and the increasing demand for accessible, personalized care, particularly in international markets. Eucalyptus’s existing infrastructure and expertise provide a shortcut to expansion, but also introduce integration risks and regulatory hurdles.

What we're watching

Integration Risk
Successfully integrating Eucalyptus's operations and brands into Hims & Hers' existing platform will be crucial, and potential cultural clashes or operational inefficiencies could hinder the deal's value creation.
Regulatory Landscape
The varying regulatory environments in Australia, Japan, Germany, Canada, and the UK pose a significant challenge, and Hims & Hers will need to navigate these complexities to achieve its international expansion goals.
Market Adoption
The pace at which Eucalyptus’s brands and Hims & Hers’ services are adopted by consumers in new international markets will determine the overall success of the acquisition and its impact on profitability.

Hims & Hers Expands Weight Loss Portfolio with Compounded Semaglutide

Event summary

  • Hims & Hers is now enabling providers to prescribe compounded Semaglutide pills, a needle-free alternative to Wegovy.
  • The introductory price for the compounded Semaglutide pill is $49/month for the first month, increasing to $99/month thereafter.
  • Hims & Hers doubled its facility footprint to over one million square feet in 2025, integrating pharmacy, lab testing, and R&D capabilities.
  • The compounded drug is not FDA-approved and uses a different formulation and delivery system than oral semaglutide.

The big picture

Hims & Hers’ expansion into compounded semaglutide represents a strategic bet on personalized care and affordability within the rapidly growing weight loss market. The move leverages the company’s significant infrastructure investments but introduces regulatory and competitive risks associated with compounded drugs. This strategy highlights the ongoing trend of telehealth platforms seeking to expand treatment options and disrupt traditional pharmaceutical distribution models.

What we're watching

Regulatory Scrutiny
The use of compounded drugs, particularly in a telehealth context, may attract increased scrutiny from the FDA and state regulatory bodies, potentially impacting Hims & Hers’ operational model.
Pricing Sustainability
The introductory $49/month price point is likely intended to drive adoption, but the subsequent increase to $99/month could impact customer retention and overall market penetration.
Competitive Response
Novo Nordisk and other pharmaceutical companies may accelerate the development of their own needle-free or alternative formulations, potentially eroding Hims & Hers’ competitive advantage in the weight loss market.

Hims & Hers Adds Cancer Screening via Galleri Partnership

Event summary

  • Hims & Hers has launched the Hims & Hers Multi-Cancer Test by Galleri®, a blood test for early cancer detection.
  • The test screens for signals associated with 50+ types of cancer, including those with limited screening options.
  • Hims & Hers customers can add the test to existing Labs plans for a $250 discount.
  • The partnership leverages GRAIL’s technology and Hims & Hers’ digital health platform to expand access to proactive cancer screening.

The big picture

Hims & Hers’ entry into cancer screening represents a strategic expansion beyond its core telehealth offerings, tapping into the growing demand for accessible and proactive healthcare solutions. This partnership with GRAIL highlights the increasing convergence of digital health platforms and advanced diagnostic technologies, potentially disrupting traditional cancer screening pathways. The move also underscores the broader trend of consumers seeking more personalized and preventative healthcare options, driven by rising healthcare costs and a desire for greater control over their health.

What we're watching

Adoption Rate
The success of this initiative hinges on customer adoption of the test, which will be influenced by price sensitivity and awareness of MCED benefits.
Regulatory Scrutiny
As MCED tests become more prevalent, increased regulatory scrutiny from the FDA and CMS is likely, potentially impacting reimbursement and test validation requirements.
Clinical Validation
Continued clinical validation of the Galleri test's accuracy and impact on patient outcomes will be crucial to maintain trust and expand insurance coverage.

Hims & Hers Leverages Super Bowl Ad to Highlight Healthcare Disparity

Event summary

  • Hims & Hers is returning to the Super Bowl with a new advertisement, ‘Rich People Live Longer’.
  • The ad campaign highlights a 7-year average life expectancy difference between the top 1% and the bottom 50% of Americans based on median household income.
  • The campaign aims to position proactive, personalized healthcare as a right, not a luxury.
  • The ad features Grammy-winning artist and health equity advocate Common.

The big picture

Hims & Hers' Super Bowl ad represents a calculated risk, leveraging a high-profile platform to address a growing societal concern about healthcare inequality. The company is attempting to redefine its brand beyond a direct-to-consumer pharmacy, positioning itself as a champion for accessible care. This strategy, while potentially impactful, faces challenges given the entrenched nature of the US healthcare system and the potential for consumer skepticism.

What we're watching

Consumer Response
How consumers react to the campaign's messaging and whether it translates to increased platform adoption and brand loyalty remains to be seen, especially given the potential for backlash.
Regulatory Scrutiny
The campaign's direct challenge to the existing healthcare system could attract increased scrutiny from regulators regarding marketing practices and claims of accessibility.
Competitive Landscape
Whether competitors will attempt to capitalize on the narrative of accessible healthcare and how Hims & Hers will differentiate its offerings will be crucial for maintaining market share.
CID: 622